Essai en cours de recrutement = ; Essai en cours = ; Financé par un membre IRDiRC = ; Membre d'un ERN =

Essai(s) clinique(s) national(aux)

ALLEMAGNE

Sachsen
CHEMNITZ

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias -DE-

Klinikum Chemnitz gGmbH

Zentrum für Innere Medizin II

Plus de détails

ESPAGNE

Cataluña
BARCELONA

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias - ES

Hospital Clínic de Barcelona

Servicio de Dermatología

Plus de détails

ESPAGNE

Murcia
EL PALMAR, MURCIA

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias - ES

Hospital Clínico Universitario Virgen de la Arrixaca

Plus de détails

ESPAGNE

Navarra
PAMPLONA

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias - ES

Clínica Universidad de Navarra

Unidad de Hepatología

Plus de détails

Essai(s) clinique(s) multinational(aux)

ETATS-UNIS

Massachusetts
CAMBRIDGE

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc.

Plus de détails